Stockscreener 앱 받기
31.28
0.06%
-0.02
전일 마감가:
$31.30
열려 있는:
$31.55
하루 거래량:
498.67K
Relative Volume:
0.96
시가총액:
$1.50B
수익:
$723.55M
순이익/손실:
$157.72M
주가수익비율:
10.43
EPS:
3
순현금흐름:
$170.15M
1주 성능:
+0.84%
1개월 성능:
-13.18%
6개월 성능:
-33.26%
1년 성능:
-38.97%
1일 변동 폭
$30.96
$31.60
1주일 범위
$30.34
$31.65
52주 변동 폭
$30.34
$56.38
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
명칭
Amphastar Pharmaceuticals Inc
전화
909-980-9484
주소
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
AMPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
31.28 | 1.50B | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | 개시 | Wells Fargo | Equal Weight |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2023-11-17 | 개시 | BofA Securities | Neutral |
| 2023-07-25 | 재개 | Jefferies | Buy |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-07-29 | 개시 | CapitalOne | Overweight |
| 2022-01-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | 개시 | Northland Capital | Outperform |
| 2019-03-13 | 다운그레이드 | Needham | Buy → Hold |
| 2019-03-13 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-03-13 | 재확인 | Needham | Buy |
| 2017-12-01 | 재확인 | Needham | Buy |
| 2017-11-09 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | 재확인 | Needham | Buy |
| 2017-03-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-05-10 | 재확인 | Needham | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2015-06-19 | 재확인 | Needham | Buy |
| 2015-06-03 | 개시 | Raymond James | Strong Buy |
| 2014-07-21 | 개시 | Needham | Buy |
모두보기
Amphastar Pharmaceuticals Inc 주식(AMPH)의 최신 뉴스
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update - MarketBeat
Can Amphastar's High-Value Pipeline Strategy Show Results? Q4 Earnings Preview - StockTitan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month LowHere's Why - MarketBeat
Amphastar Pharmaceuticals: A Gradual Strategy (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference - ACCESS Newswire
Amphastar Pharmaceuticals (AMPH) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Dextrose Injection Market: Demand, Growth, and Innovations 2025-2032 | Pfizer Inc., Amphastar Pharmaceuticals Inc - openPR
Yousif Capital Management LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
How the (AMPH) price action is used to our Advantage - Stock Traders Daily
State of Alaska Department of Revenue Sells 342 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Polaris Capital Management LLC Buys Shares of 24,500 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks - The Globe and Mail
Amphastar stock hits 52-week low at $31.54 amid market challenges - Investing.com Canada
Amphastar stock hits 52-week low at $34.08 amid market challenges - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Simply Wall St
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap DownShould You Sell? - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by Piper Sandler - MarketBeat
Boston Trust Walden Corp Purchases 439,281 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week LowHere's Why - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to Neutral - Defense World
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Sees Large Growth in Short Interest - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Piper Sandler cuts Amphastar stock rating, slashes price target By Investing.com - Investing.com Canada
Market Resilience: Amphastar Pharmaceuticals Inc (AMPH) Finishes Weak at 33.39, Down -4.24 - The Dwinnex
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66 - Marketscreener.com
Piper Sandler cuts Amphastar stock rating, slashes price target - MSN
Long Term Trading Analysis for (AMPH) - Stock Traders Daily
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46 -February 03, 2025 at 10:16 am EST - Marketscreener.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Amphastar Pharmaceuticals is Now Oversold (AMPH) - Nasdaq
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 - ACCESS Newswire
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 - ACCESS Newswire
Amphastar Receives FDA Approval for Vasopressin - ACCESS Newswire
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023 - ACCESS Newswire
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program - ACCESS Newswire
(AMPH) Technical Data - Stock Traders Daily
Amphastar Receives FDA Approval for Ganirelix Acetate Injection - ACCESS Newswire
Possible Bearish Signals With Amphastar Pharmaceuticals Insiders Disposing Stock - Simply Wall St
Amphastar Pharmaceuticals Inc (AMPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amphastar Pharmaceuticals Inc 주식 (AMPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Option Exercise |
11.33 |
7,000 |
79,310 |
125,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 13 '24 |
Sale |
45.23 |
8,000 |
361,840 |
118,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Sale |
44.42 |
7,000 |
310,975 |
118,469 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Option Exercise |
19.52 |
10,000 |
195,200 |
40,471 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Sale |
43.77 |
10,000 |
437,702 |
30,471 |
3.23%
3.94%
자본화:
|
볼륨(24시간):